• Skip to main content
  • Skip to footer
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

CN Bio Innovations marks World Hepatitis Day by signing research agreement with Imperial College London

July 28, 2014

Collaboration will develop and further validate CN Bio’s in vitro model of Hepatitis B liver infection

Oxford, UK, 28 July 2014: CN Bio Innovations Ltd (CN Bio), an expert in developing leading edge human biomimetic platforms to test and develop therapeutics for serious diseases, announced today that it has signed a research agreement with Imperial College London to advance the development of in vitro models of liver infection based on the company’s LiverChip™ platform. The announcement coincides with the WHO World Hepatitis Day and serves to further emphasise the current efforts being forged by industry and academia to find cures for Hepatitis and other serious liver diseases.

Validation of in vitro system for liver infection

Dr Marcus Dorner, who is the Lead Principal Investigator on the new project at Imperial, commented: “Unfortunately, the liver models currently in widespread use often fail to accurately reproduce what we see in vivo, limiting their utility.” He continued: “We’re excited about the early potential shown by CN Bio’s platform for studying the pathology of Hepatitis B and look forward to presenting our results from this ongoing program of work at a number of international conferences this Fall.”

Forging enabling partnerships and alliances with Academia and Industry

Dr Emma Sceats, COO at CN Bio, said: “We are pleased to extend our relationship with Imperial through this new collaboration with Dr Dorner and Professor Mark Thursz. Forging partnerships with key opinion leaders and academic groups is a cornerstone of our research and development strategy whose goal is to bring to market biomimetic models that will provide unique insights into liver biology and disease pathology. Through alliance partnerships with major pharmaceutical and biotech companies, CN Bio’s experts are using these models to accelerate the development of drugs that will provide life-changing treatment and cures for patients affected by serious liver diseases.”

Early results from the collaboration are due to be presented at a number of conferences including the American Association for the Study of Liver Diseases (AASLD) meeting in Boston, November 7–11, 2014. For more details visit the CN Bio website.

About CN Bio Innovations (CN Bio)

CN Bio Innovations (CN Bio), formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio provides human biomimetic platforms for the testing and development of therapeutics for serious human diseases. Working closely with academic pioneers in the bio-engineering field, CN Bio is developing next generation tissue and disease models which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market.

Release Status For immediate release
Commercial Enquiries CN Bio Innovations
Ian Taylor
Commercial Director
T: +44 (0) 1865 309 600
E: [email protected]
W: www.cn-bio.com
   
Media Enquiries BioStrata
Paul Avery
Managing Director
T: +44 (0) 1223 828 200
E: [email protected]
W: www.biostratamarketing.com

 

Category iconPress releases

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development June 10, 2025
  • CN Bio expands access to OOC solutions for APAC customers with distributor agreement in South Korea May 20, 2025
  • Microphysiological systems for mAbs development: how do they address animal limitations? May 1, 2025
Cyber Essentials Logo